Table 3 Comparison between SCD patients without an HSCT indication and those with ≥ 1 HSCT indication regarding the different studied parameters

Demographic/clinical and treatment data

 Gender male/female

28/31 (47.5%/52.5%)

43/26 (62.3%/37.7%)

0.092

 Weight (kg) (mean ± SD)

30.97 ± 13.01

30.41 ± 19.52

0.851

 Height (cm) (mean ± SD)

127.25 ± 15.62

125 ± 18.99

0.469

 Splenomegaly yes/no

4/55 (6.8%/93.2%)

16/53 (23.2%/76.8%)

0.013^*

 Frequency of yearly transfusions (mean ± SD)

2.56 ± 1.76

8.57 ± 4.03

 < 0.0001^*

 Hydroxyurea treatment yes/no

56/3 (94.9%/5.1%)

69/0 (100%/0%)

0.058

 Hydroxyurea dose in mg/kg (mean ± SD)

18.38 ± 6.05

21.43 ± 5.74

0.005^*

SCD phenotype

 Sβ

27 (45.8%)

42 (60.9%)

0.087

 SS

32 (54.2%)

27 (39.1%)

Laboratory data (mean ± SD)

 Hemoglobin (gm/dl)

9.17 ± 1.31

7.96 ± 1.20

 < 0.001^*

 TLC (× 10³/mm³)

8.48 ± 3.43

10.24 ± 4.74

0.039^*

 PLT (× 10³/mm³)

334.80 ± 126.08

313.33 ± 165.56

0.176

 Reticulocyte count (%)

4.63 ± 3.45

8.27 ± 4.76

 < 0.001^*

 Serum ferritin (ng/ml)

434.27 ± 348.49

1020.74 ± 588.33

 < 0.001^*

 AST (U/l)

35.88 ± 13.94

47.57 ± 21.98

 < 0.001^*

 HbS (%)

69.13 ± 10.29

70.11 ± 11.57

0.615

 HbF (%)

5.49 ± 8.26

7.08 ± 7.15

0.245